{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:25Z","timestamp":1791252805476,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cbpa.2023.102319","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T12:13:44Z","timestamp":1686053624000},"page":"102319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis"],"prefix":"10.1016","volume":"75","author":[{"given":"Nicholas L.","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Michael","family":"Petrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2023.102319_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-biochem-061516-044518","article-title":"Protein misfolding diseases","volume":"86","author":"Hartl","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cbpa.2023.102319_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/17474086.2014.858594","article-title":"Immunoglobulin light chain amyloidosis","volume":"7","author":"Merlini","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.cbpa.2023.102319_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.cbpa.2023.102319_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/febs.16390","article-title":"Antibodies gone bad \u2013 the molecular mechanism of light chain amyloidosis","volume":"290","author":"Absmeier","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.cbpa.2023.102319_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (AL) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cbpa.2023.102319_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cbpa.2023.102319_bib8","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.cbpa.2023.102319_bib9","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2023.102319_bib10","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2023.102319_bib11","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.jmb.2016.08.021","article-title":"The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains","volume":"428","author":"Morgan","year":"2016","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.cbpa.2023.102319_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16953-7","article-title":"Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity","volume":"7","author":"Oberti","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2023.102319_sref13","first-page":"645","article-title":"Light chain stabilization: a therapeutic approach to ameliorate al amyloidosis","volume":"2","author":"Morgan","year":"2021","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.cbpa.2023.102319_sref14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jmb.2013.10.016","article-title":"Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations","volume":"426","author":"Blancas-Mej\u00eda","year":"2014","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.cbpa.2023.102319_sref15","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2023.102319_bib16","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2023.102319_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.cbpa.2023.102319_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0914","article-title":"Does protein aggregation drive postmitotic tissue degeneration?","volume":"13","author":"Kelly","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib20","doi-asserted-by":"crossref","first-page":"20845","DOI":"10.1021\/jacs.0c10629","article-title":"Modulation of amyloidogenic protein self-assembly using tethered small molecules","volume":"142","author":"Cawood","year":"2020","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.cbpa.2023.102319_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.sbi.2021.11.009","article-title":"Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation","volume":"72","author":"Chiti","year":"2022","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.cbpa.2023.102319_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2022.2126308","article-title":"Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response","volume":"30","author":"Monteiro","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.cbpa.2023.102319_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2023.102319_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","article-title":"Immunoglobulin light chain amyloidosis and the kidney","volume":"61","author":"Gertz","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.cbpa.2023.102319_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506120802676781","article-title":"AL-Base: A visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences","volume":"16","author":"Bodi","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.cbpa.2023.102319_bib28","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1073\/pnas.1817538116","article-title":"Role of domain interactions in the aggregation of full-length immunoglobulin light chains","volume":"116","author":"Rennella","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2023.102319_bib29","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1021\/bi00715a031","article-title":"Binding of 2,4-dinitrophenyl compounds and other small molecules to a crystalline lambda-type Bence-Jones dimer","volume":"13","author":"Edmundson","year":"1974","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2023.102319_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0161-5890(84)90041-5","article-title":"A\u00a0search for site-filling ligands in the Mcg Bence-Jones dimer: crystal binding studies of fluorescent compounds","volume":"21","author":"Edmundson","year":"1984","journal-title":"Mol Immunol"},{"key":"10.1016\/j.cbpa.2023.102319_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10935","article-title":"Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain","volume":"4","author":"Brumshtein","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.cbpa.2023.102319_sref32","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/acs.jmedchem.1c00339","article-title":"Discovery of potent coumarin-based kinetic stabilizers of amyloidogenic immunoglobulin light chains using structure-based design","volume":"64","author":"Yan","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cbpa.2023.102319_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127356","article-title":"Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins","volume":"30","author":"Yan","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2023.102319_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ijch.202300002","article-title":"Crystal structures of diaryl hydrazone and sulfone stabilizers in complex with an amyloidogenic light chain reveal an alternate ligand-binding cavity","author":"Yan","year":"2023","journal-title":"Isr J Chem"},{"key":"10.1016\/j.cbpa.2023.102319_bib35","doi-asserted-by":"crossref","first-page":"14101","DOI":"10.1021\/bi991131j","article-title":"Thermodynamic instability of human \u03bb6 light chains: correlation with fibrillogenicity","volume":"38","author":"Wall","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2023.102319_bib36","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1021\/acs.biochem.7b00579","article-title":"Incomplete refolding of antibody light chains to non-native, protease-sensitive conformations leads to aggregation: a mechanism of amyloidogenesis in patients?","volume":"56","author":"Morgan","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2023.102319_sref37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jmb.2004.08.085","article-title":"Probing the high energy states in proteins by proteolysis","volume":"343","author":"Park","year":"2004","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.cbpa.2023.102319_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2018.05.003","article-title":"Cryptic binding sites on proteins: definition, detection, and druggability","volume":"44","author":"Vajda","year":"2018","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.cbpa.2023.102319_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/prot.340160304","article-title":"Principles and pitfalls in designing site-directed peptide ligands","volume":"16","author":"Edmundson","year":"1993","journal-title":"Proteins"},{"key":"10.1016\/j.cbpa.2023.102319_sref40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128571","article-title":"Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site","volume":"60","author":"Yan","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2023.102319_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.sbi.2009.12.009","article-title":"Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses","volume":"20","author":"Connelly","year":"2010","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.cbpa.2023.102319_bib42","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/ja908562q","article-title":"A\u00a0substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity","volume":"132","author":"Choi","year":"2010","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.cbpa.2023.102319_bib43","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cbpa.2023.102319_bib44","doi-asserted-by":"crossref","first-page":"13722","DOI":"10.1021\/bi00042a002","article-title":"Reduced albumin binding promotes the stability and activity of topotecan in human blood","volume":"34","author":"Mi","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2023.102319_bib45","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1073\/pnas.91.12.5446","article-title":"A\u00a0role for destabilizing amino acid replacements in light-chain amyloidosis","volume":"91","author":"Hurle","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2023.102319_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52300","article-title":"Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation","volume":"9","author":"Kazman","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.cbpa.2023.102319_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137716","article-title":"Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes","volume":"10","author":"McWilliams-Koeppen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2023.102319_bib48","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","article-title":"Cell damage in light chain amyloidosis fibril internalization, toxicity and cell-mediated seeding","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J\u00a0Biol Chem"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593123000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593123000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:54:17Z","timestamp":1761274457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593123000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"alternative-id":["S1367593123000571"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2023.102319","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2023.102319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102319"}}